Benzothiazole derivatives as novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1
- 27 March 2006
- journal article
- Published by Elsevier BV in Molecular and Cellular Endocrinology
- Vol. 248 (1-2), 214-217
- https://doi.org/10.1016/j.mce.2005.10.022
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- 11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseasesExpert Opinion on Therapeutic Patents, 2005
- Conformational Flexibility in Crystal Structures of Human 11β-Hydroxysteroid Dehydrogenase Type I Provide Insights into Glucocorticoid Interconversion and Enzyme RegulationPublished by Elsevier BV ,2005
- 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid ResponseEndocrine Reviews, 2004
- Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose TissueProceedings of the 1972 Laurentian Hormone Conference, 2004
- Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1Journal of Medicinal Chemistry, 2002
- The Protein Data BankNucleic Acids Research, 2000
- Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2JCI Insight, 1999
- Development and validation of a genetic algorithm for flexible dockingJournal of Molecular Biology, 1997
- Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activationJournal of Clinical Endocrinology & Metabolism, 1995
- LOCALISATION OF 11β-HYDROXYSTEROID DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTORThe Lancet, 1988